On Target is a recurring feature from STAT that dives deep into the most promising drug targets in oncology. This column is adapted from the new STAT Report: Targeting cancer: the new frontier of ...
Antibody-Drug Conjugate Is Tolerable, Active in CLDN6-Positive Solid Tumors Including Ovarian Cancer
TORL-1-23 showed promising efficacy in CLDN6-positive advanced solid tumors, with varying ORRs across different doses, highest in ovarian cancer at 2.4 mg/kg. The ADC was well tolerated, with ...
Emphasis on Potential Clinical Applications and Enhancing RNA Sample Quality Researchers are beginning to look at tissue microarrays (TMA) from different perspectives, including one with a strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback